ConductScience.org, home

Library / Trials

Digital Multimodal Rehabilitation for People With Post-acute COVID-19 Syndrome.

NCT05846126, Not applicable, Completed, Consorci Sanitari de Terrassa

Trial 10

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

FieldValueSource
TitleDigital Multimodal Rehabilitation for People With Post-acute COVID-19 Syndrome.ClinicalTrials.gov
NCT numberNCT05846126ClinicalTrials.gov
StatusCompletedClinicalTrials.gov
PhasesNot applicableClinicalTrials.gov
Enrollment172 participants, actualClinicalTrials.gov
Lead sponsorConsorci Sanitari de TerrassaClinicalTrials.gov
ConditionsPost-COVID SyndromeClinicalTrials.gov
InterventionsRehabCovid_Telematic, RehabCovid_ImmersiveVR, Control_ConditionClinicalTrials.gov
First posted2023-05-06ClinicalTrials.gov
Last updated2026-04-30ClinicalTrials.gov

Registered outcomes 27

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescriptionSource
PrimaryDifferences between groups in scores of global cognitionBefore the intervention and 12 weeks later
Global cognition was assessed with the Montreal Cognitive Assessment (MoCA) a screening tool designed to identify mild cognitive impairment (MCI) and other cognitive deficits. The MoCA takes around 10-15 minutes to complete and consists of 30 items (range=0-30). Higher scores mean a better outcome.
ClinicalTrials.gov
PrimaryDifferences between groups in scores of selective attention, inhibition, and processing speedBefore the intervention and 12 weeks later
Selective attention, inhibition, and processing speed are measured with the Stroop Color and Word Test. Participants are asked to name the color of a series of color patches (Stroop Color Naming), read a series of color words (Stroop Word Reading), and name the color of a series of color words where the word and color do not match (e.g., the word "red" written in blue ink), Stroop Color-Word Interference. Higher scores mean a better outcome.
ClinicalTrials.gov
PrimaryDifferences between groups in scores of Visual scanning and processing speedBefore the intervention and 12 weeks later
Visual scanning and processing speed are measured with the Trail-Making Test-A version. Participants are asked to connect a series of numbered circles on a page in numerical order. Higher scores mean a better outcome.
ClinicalTrials.gov
PrimaryDifferences between groups in scores of Executive functioning and cognitive flexibilityBefore the intervention and 12 weeks later
Executive functioning and cognitive flexibility are measured with the Trail-Making Test-B version. Participants are asked to connect a series of circles that contain both numbers and letters in alternating numerical and alphabetical order. Higher scores mean a better outcome.
ClinicalTrials.gov
PrimaryDifferences between groups in scores of auditory attentionBefore the intervention and 12 weeks laterAuditory attention is measured with Digit Span Forward from WAIS-IV. Participants are asked to repeat numbers in the same order as read aloud by the examiner. Higher scores mean a better outcome.ClinicalTrials.gov
PrimaryDifferences between groups in scores of working memory_DSBBefore the intervention and 12 weeks later
Working memory is measured with Digit Span Backward from WAIS-IV. Participants are asked to repeat the numbers in the reverse order of that presented by the examiner. Higher scores mean a better outcome.
ClinicalTrials.gov
PrimaryDifferences between groups in scores of Perceptual ReasoningBefore the intervention and 12 weeks later
Perceptual Reasoning is measured with Matrices from the WAIS-IV. Participants are presented with a pattern or design with one missing piece and are asked to select the correct piece from a set of options to complete the pattern. Higher scores on the Perceptual Reasoning Index mean a better outcome.
ClinicalTrials.gov
PrimaryDifferences between groups in scores of sustained attention and impulsivityBefore the intervention and 12 weeks later
Conners Continuous Performance Test - 2nd edition (CPT-II) is task-oriented computerised assessment of attention-related problems. Participants are presented with a repetitive array of visual stimuli on a computer screen for 14 min. Participants are instructed to press the space bar every time a letter other than "X" appears and to not press the space bar when "X" appears. The rate of stimulus presentation varies according to 1, 2, and 4 s intervals throughout the task. Measures: Correct Detection (Higher rates indicate better outcome), Reaction times (Lower scores indicate better outcome), Omission errors (Lower rates indicate better outcome), and Commission errors (Lower rates indicate better outcome).
ClinicalTrials.gov
PrimaryDifferences between groups in scores of processing speedBefore the intervention and 12 weeks later
The Digit Symbol Coding subtest from the WAIS-III is a neuropsychological assessment instrument for the detection of brain dysfunction in children and adults. It consists of replacing symbols that lack verbal meaning with numbers based on a key. Higher scores indicate better outcomes.
ClinicalTrials.gov
PrimaryDifferences between groups in scores of verbal memory and learningBefore the intervention and 12 weeks later
Verbal memory and learning are measured with the Rey Auditory Verbal Learning Test (RAVLT). It is a word-learning test where five presentations of a 15-word list are given, each followed by an attempted recall. This is followed by a second 15-word interference list (list B), followed by a recall of list A. Delayed recall and recognition are also tested. Higher scores mean a better outcome.
ClinicalTrials.gov
PrimaryDifferences between groups in scores of phonetic fluencyBefore the intervention and 12 weeks later
Phonetic fluency is measured with the FAS test. It consists of saying words that start with a certain letter, as many words as possible must be mentioned during a specific time of 1 minute. The standard administration of the test provides three letters, the most used are the letters F, A, and S. Higher scores indicate better performance.
ClinicalTrials.gov
PrimaryDifferences between groups in scores of semantic verbal fluencyBefore the intervention and 12 weeks laterSemantic verbal fluency is measured with the ANIMAL test. It consists of generating the name of as many species of animals as possible within 1min. Higher scores indicate better performance.ClinicalTrials.gov
PrimaryDifferences between groups in scores of memory and everyday forgetfulnessBefore the intervention and 12 weeks later
Memory and everyday forgetfulness are measured with The Memory Failures of Everyday-MFE Questionnaire is a self-reported test that allows an assessment of memory and everyday forgetfulness. It is a unifactorial questionnaire and consists of 30 items. The total score results from the sum of the scores in each item, from 1 to 30. The MFE can assess the current situation of the patients and their evolution long-term or changes due to treatment. Scores \<8 represent an optimal memory function. Lower scores indicate better outcomes.
ClinicalTrials.gov
SecondaryDifferences between groups in scores of anxietyBefore the intervention and 12 weeks later
Anxiety is measured with the 7-item Generalized Anxiety Disorder Scale (GAD-7), a Likert-type scale with questions ranging from "not at all" (0 points) to "nearly every day" (3 points). The maximum score is 24. Higher scores mean a worse outcome.
ClinicalTrials.gov
SecondaryDifferences between groups in scores of depressionBefore the intervention and 12 weeks later
Depression is measured with the Patient Health Questionnaire-9 (PHQ-9) which scores each of the 9 DSM-IV criteria as "not at all" (0 points) to "nearly every day" (3 points). Higher scores mean a worse outcome.
ClinicalTrials.gov
SecondaryDifferences between groups in scores of Mindfulness levelsBefore the intervention and 12 weeks later
Mindfulness levels are measured with The Mindful Attention Awareness Scale (MAAS) assesses an individual's level of mindfulness, including attention, awareness, and non-judgment. The 15-item self-report questionnaire uses a 6-point Likert scale to measure an individual's general tendency to be aware of and attentive to their current experience. Scores on the MAAS range from 15 to 90, with higher scores indicating greater levels of mindfulness. A higher score suggests better outcome.
ClinicalTrials.gov
SecondaryDifferences between groups in scores of FatigueBefore the intervention and 12 weeks later
Fatigue is measured with the Chalder Fatigue Scale, an 11-item questionnaire measuring the severity of physical and mental fatigue on two separate subscales. Seven items represent physical fatigue (items 1-7) and 4 represent mental fatigue (items 8-11). Each item " less than usual" (0) to " much more than usual" (3). The ratings of items are added together to calculate the total score (range=0-33). High scores represent high levels of fatigue.
ClinicalTrials.gov
SecondaryDifferences between groups in scores of psychological flexibilityBefore the intervention and 12 weeks later
Psychological flexibility is measured with the Acceptance and Action Questionnaire, a 7-point Likert scale, ranging from 1 ("never true") to 7 ("always true"), indicating how frequently they experience the described behavior or feeling in their daily lives. The scale has 9 items and the total score ranges from 9 to 63, with higher scores indicating greater levels of psychological flexibility (better outcome).
ClinicalTrials.gov
SecondaryDifferences between groups in FunctionalityBefore the intervention and 12 weeks later
Functionality is measured with a 12-item World Health Organization Disability Assessment Schedule-II (WHODAS-II). Patients are asked to state the level of difficulty experienced, considering how they usually do the activity. The scale scores each item as "none" (1) to "cannot do" (5). The total score is calculated with an SPSS syntax, and the range varies from 0 to 100, with higher scores reflecting more significant disability.
ClinicalTrials.gov
SecondaryDifferences between groups in scores of Sleep QualityBefore the intervention and 12 weeks later
Sleep Quality is measured with The Pittsburgh Sleep Quality Index (PSQI). This test presents 24 items, although only 19 are taken into account for the correction. This test is divided into 7 dimensions, namely, sleep quality, sleep onset latency, sleep duration, sleep efficiency, sleep disturbances, hypnotic drugs, and daytime dysfunction. Higher scores indicate worse sleep quality.
ClinicalTrials.gov

Outcomes 0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured asSource

Results by group 0

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnitsSource

Participant flow 0

How many started, completed or left each group, period by period.

PeriodMilestoneGroupParticipantsUnits countedSource

Adverse events 0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

TypeEventOrgan systemGroupAffectedAt riskEventsSource

Adverse event totals 0

The totals the trial posted for each group.

TotalGroupAffectedAt riskSource

Papers 2

The papers the trial lists on ClinicalTrials.gov.

PMIDListed asSource
41851162DERIVEDPubMed
42058732DERIVEDPubMed

Grants 0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

ProjectTitlePrincipal investigatorsOrganizationFunderFiscal yearsSource

Trial comparisons 0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

ComparisonSource

Tests 8

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

TestNamed asSource
Continuous Performance TestPrimary outcomeConductCognition
Digit Span TestPrimary outcomeConductCognition
Stroop Color-Word TestPrimary outcomeConductCognition
Symbol CodingPrimary outcomeConductCognition
Trail Making Test APrimary outcomeConductCognition
Trail Making Test BPrimary outcomeConductCognition
Verbal FluencyPrimary outcomeConductCognition
Verbal LearningPrimary outcomeConductCognition

Source 5

FieldValueSource
Releasetrials-2026-11-12-0.4.0ClinicalTrials.gov
Release manifest SHA-2560f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4ClinicalTrials.gov
Registry capture2026-11-12ClinicalTrials.gov
Results copy, AACT2026-03-23ClinicalTrials.gov
NIH clinical studies file2026-11-13ClinicalTrials.gov

The same record as JSON

Release trials-2026-11-12-0.4.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)